The short version of Secretagogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Solubility | Freely soluble in water and polar solvents | Dissolution may require brief mixing |
| Typical storage temperature | Minus 20 degrees Celsius or below | Dry, desiccated, protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Purity plus identity confirmation |
| Common synonyms | Ipamorelin acetate, NNC 26-0161 | Research code used in early literature |
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.
Under the influence of androgens, the larynx (or voice box) grows in both sexes. This growth is far more prominent in males, causing the male voice to drop and deepen, sometimes abruptly but rarely "overnight", about one octave, because the longer and thicker vocal folds have a lower fundamental frequency. Before puberty, the larynx of males and females is about equally small.
== Kingdom of the Netherlands (1815–present) == At the Congress of Vienna in 1815, William I ceded his ancestral German lands—making him the last sovereign Prince of Orange of his dynasty—in exchange for being proclaimed, as William I, King of the Netherlands and Grand Duke of Luxembourg. The kingdom was enlarged with the Southern Netherlands. Consequently, he appears under both titles during his respective reigns. The kingdom included Belgium until its secession in 1830. To finalize this separation between Belgium an the Netherlands, the Treaty of London (1839) designated the Dutch monarchs as Dukes of Limburg; this newly created duchy (formed from the remaining Dutch part of Limburg) was integrated into the German Confederation until its dissolution in 1866 as territorial compensation for Luxembourgish lands ceded to Belgium. The personal union with Luxembourg ended upon the death of King William III in 1890; since the Dutch throne passed to his daughter Wilhelmina, the Grand Ducal crown reverted to the closest male heir, Duke Adolphe. The monarchs also reigned over the realm's overseas territories; initially as colonies, and from 1954 onwards as equal constituent countries within the Kingdom, including the Dutch East Indies (until 1949), Dutch New Guinea (until 1962), Suriname (until 1975), and the Netherlands Antilles.
Sources: en.wikipedia.org
=== MeSH D12.644.548 – peptide hormones === MeSH D12.644.548.009 – activins MeSH D12.644.548.009.500 – inhibin-beta subunits MeSH D12.644.548.014 – adiponectin MeSH D12.644.548.020 – atrial natriuretic factor MeSH D12.644.548.100 – bombesin MeSH D12.644.548.150 – calcitonin MeSH D12.644.548.200 – corticotropin-releasing hormone MeSH D12.644.548.275 – gastric inhibitory polypeptide MeSH D12.644.548.280 – gastrins MeSH D12.644.548.343 – glucagon precursors MeSH D12.644.548.343.249 – enteroglucagons MeSH D12.644.548.343.249.500 – glucagon-like peptide 1 MeSH D12.644.548.343.500 – glucagon MeSH D12.644.548.387 – inhibins MeSH D12.644.548.387.500 – inhibin-beta subunits MeSH D12.644.548.393 – insulin MeSH D12.644.548.393.408 – insulin, isophane MeSH D12.644.548.393.532 – insulin, long-acting MeSH D12.644.548.393.788 – proinsulin MeSH D12.644.548.393.788.250 – c-peptide MeSH D12.644.548.400 – leptin MeSH D12.644.548.500 – motilin MeSH D12.644.548.560 – msh release-inhibiting hormone MeSH D12.644.548.580 – msh-releasing hormone MeSH D12.644.548.585 – natriuretic peptide, c-type MeSH D12.644.548.587 – pancreatic polypeptide MeSH D12.644.548.588 – parathyroid hormone-related protein MeSH D12.644.548.590 – parathyroid hormone MeSH D12.644.548.590.850 – teriparatide MeSH D12.644.548.592 – peptide phi MeSH D12.644.548.595 – peptide yy MeSH D12.644.548.600 – pituitary hormone release inhibiting hormones MeSH D12.644.548.620 – pituitary hormone-releasing hormones MeSH D12.644.548.691 – pituitary hormones MeSH D12.644.548.691.525 – pituitary hormones, anterior MeSH D12.644.548.691.525.343 – gonadotropins, pituitary MeSH D12.644.548.691.525.343.288 – follicle stimulating hormone MeSH D12.644.548.691.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D12.644.548.691.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463 – luteinizing hormone MeSH D12.644.548.691.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.343.463.500 – luteinizing hormone, beta subunit MeSH D12.644.548.691.525.343.583 – menotropins MeSH D12.644.548.691.525.343.583.500 – urofollitropin MeSH D12.644.548.691.525.425 – growth hormone MeSH D12.644.548.691.525.425.875 – human growth hormone MeSH D12.644.548.691.525.525 – prolactin MeSH D12.644.548.691.525.690 – pro-opiomelanocortin MeSH D12.644.548.691.525.690.130 – corticotropin MeSH D12.644.548.691.525.690.130.050 – alpha-msh MeSH D12.644.548.691.525.690.130.200 – cosyntropin MeSH D12.644.548.691.525.690.480 – lipotropin MeSH D12.644.548.691.525.690.583 – melanocyte-stimulating hormones MeSH D12.644.548.691.525.690.583.050 – alpha-msh MeSH D12.644.548.691.525.690.583.075 – beta-msh MeSH D12.644.548.691.525.690.583.115 – gamma-msh MeSH D12.644.548.691.525.883 – thyrotropin MeSH D12.644.548.691.525.883.249 – glycoprotein hormones, alpha subunit MeSH D12.644.548.691.525.883.500 – thyrotropin, beta subunit MeSH D12.644.548.691.692 – pituitary hormones, posterior MeSH D12.644.548.691.692.433 – oxytocin MeSH D12.644.548.691.692.781 – vasopressins MeSH D12.644.548.691.692.781.100 – argipressin MeSH D12.644.548.691.692.781.100.250 – deamino arginine vasopressin MeSH D12.644.548.691.692.781.400 – lypressin MeSH D12.644.548.691.692.781.400.350 – felypressin MeSH D12.644.548.691.692.781.700 – ornipressin MeSH D12.644.548.691.692.881 – vasotocin MeSH D12.644.548.726 – placental hormones MeSH D12.644.548.726.367 – chorionic gonadotropin MeSH D12.644.548.726.367.125 – chorionic gonadotropin, beta subunit, human MeSH D12.644.548.726.367.562 – glycoprotein hormones, alpha subunit MeSH D12.644.548.726.451 – gonadotropins, equine MeSH D12.644.548.726.692 – placental lactogen MeSH D12.644.548.762 – relaxin MeSH D12.644.548.786 – resistin MeSH D12.644.548.810 – secretin MeSH D12.644.548.857 – somatostatin MeSH D12.644.548.869 – thymosin MeSH D12.644.548.905 – urotensins MeSH D12.644.548.952 – vasoactive intestinal peptide
== Research == Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. It was created by Tanox under the code name TNX-650, and a phase I clinical trial for refractory Hodgkin's lymphoma had been performed when Genentech acquired Tanox in 2007. It has successfully completed a phase II clinical trial for the treatment of asthma.
== Causes == It is believed this syndrome may represent an auriculo-autonomic headache or be part of the group of disorders known as trigeminal autonomic cephalgias, which includes cluster headaches. It is more often associated with migraine in younger people, while late-onset RES may result from pathology of the upper cervical spine or trigeminal autonomic cephalgia. Stress can affect and or cause flare ups.
Tobacco etch virus (TEV) is a plant virus in the genus Potyvirus and family Potyviridae. Like other members of the genus Potyvirus, TEV has a monopartite positive-sense, single-stranded RNA genome surrounded by a capsid made from a single viral encoded protein. The virus is a filamentous particle that measures about 730 nm in length. It is transmissible in a non-persistent manner by more than 10 species of aphids including Myzus persicae. It also is easily transmitted by mechanical means but is not known to be transmitted by seeds.
Sources: en.wikipedia.org
The amine on AICAR is much less nucleophillic than its counterpart on GAR due to delocalization of electrons in AICAR through conjugation. Therefore, the N5 nucleophile of AIRCAR must be activated for the formylation reaction to occur. Histidine 268 and Lysine 267 have been found to be essential for catalysis and are conserved in all AICAR transformylase. Histidine 268 is involved in deprotonation of the N5 nucleophile of AICAR, whereas Lysine 267 is proposed to stabilize the tetrahedral intermediate.
== Applications == DCCC has been employed to separate a wide variety of phytochemicals from their crude extracts. The long list of natural product separations includes: saponins, alkaloids, senna glycosides, monosaccarides, triterpene glycosides, flavone glycosides, xanthones, iridoid glycosides, vitamin B12, lignans, imbricatolic acid, gallic acid, carotenoids, and triterpenoids. DCCC instruments have been commercially manufactured and distributed by Büchi and Tokyo Rikakikai (Eyela).
== Operational history == In 2006 and 2007, the Stiletto participated in Trident Warrior exercises, as well as a number of other naval exercises. This included three days of mine-clearing experimentation during Exercise Howler in 2006, when the vessel was operated by the Naval Special Clearance Team-1 (NSCT-1) from the Naval Amphibious Base in Coronado. A key feature of this vessel is that it can set up a network between a special forces team by launching an unmanned aerial vehicle (UAV) that relays information between the team and boat. The Stiletto can also carry surveillance UAVs to provide reconnaissance for the SEAL team, and, using a clustered supercomputer on board, will be able to send real-time images to the team on shore. The Stiletto was selected by Time magazine as one of the Best Inventions of 2006 and one of two inventions in the Armed Forces category. In 2008, the Stiletto deployed on a 70-day mission for USSOUTHCOM as part of a joint agency operation that included the Drug Enforcement Administration and U.S. Coast Guard. In July 2012, the US Navy deployed the Stiletto to retrieve the NASA Inflatable Reentry Vehicle Experiment 3 (IRVE-3) test article, a 3 m (9.8 ft) diameter heat shield, which splashed down in the Atlantic Ocean off North Carolina after being launched on July 23 by a sounding rocket from NASA's Wallops Flight Facility. The Stiletto is referenced as a maritime demonstration craft operated by the Naval Surface Warfare Center Carderock, Combatant Craft Division, and based at Joint Expeditionary Base Little Creek-Ft Story, Va.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.
The peptide contains aromatic and imidazole groups that absorb ultraviolet light and can participate in photo-induced reactions. Those reactions can alter the molecule or generate new species. Amber glass or opaque packaging reduces the exposure.
Long-term stability data across many temperature and humidity conditions are limited. Most guidance is extrapolated from short studies on related peptides. The effect of repeated handling on a specific lot is generally not characterized.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.